Women with metastatic hormone-receptor-positive, HER2-negative breast cancer who have progressed after treatment with a CDK4/6 inhibitor may qualify for a newly opened immunotherapy study at Providence Cancer Institute.
From groundbreaking research to innovative treatments to compassionate care, everything we do at Providence Cancer Institute is for you, our patients. That’s why we’re expanding and consolidating outpatient cancer services on the 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center.
Adoptive T-cell transfer therapy is emerging as one of the most effective treatments to date for people with advanced melanoma. Now this treatment is available to patients with advanced or recurrent head and neck cancers through a clinical trial at Providence Cancer Institute.
A new phase 3 study at Providence Cancer Institute will compare the effectiveness of three different treatment regimens in men with biochemically recurrent prostate cancer.
Walter J. Urba, M.D., Ph.D.,
Member, director and endowed chair, Earle A. Chiles Research Institute, Providence Cancer Institute
The Earle A....
In his lifetime and through his estate, the late Robert W. Franz gave close to $40 million to Providence Portland Medical Foundation. Providence Cancer Institute has been renamed in his honor.
A first-of-its-kind clinical study may offer new hope to patients battling rectal cancer.
The Phase 2 study, newly underway at Providence Cancer...
With the release of her book Patient 71, Australia native Julie Randall has given cancer patients across the globe hope for life after cancer. Her remarkable story of overcoming stage IV metastatic melanoma was featured in a segment by 60 Minutes Australia chronicling her shocking diagnosis, promise to her family and determination to become “Patient 71” in an immunotherapy clinical trial at Providence Cancer Institute.
Known as "Patient 71," persistence paid off for Australian cancer patient Julie Randall
Learn more about her story ›
She now devotes her...